A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies

The vast majority of patients with plasma cell neoplasms die of progressive disease despite high response rates to novel agents. Malignant plasma cells are very radiosensitive, but the potential role of radioimmunotherapy (RIT) in the management of plasmacytomas and multiple myeloma (MM) has undergo...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Green, Damian J., Orgun, Nural N., Jones, Jon C., Hylarides, Mark D., Pagel, John M., Hamlin, Donald K., Wilbur, D.S., Lin, Yukang, Fisher, Darrell R., Kenoyer, Aimee L., Frayo, Shani L., Gopal, Ajay K., Orozco, Johnnie J., Gooley, Theodore A., Wood, Brent L., Bensinger, William I., Press, Oliver W.
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3970848/
https://ncbi.nlm.nih.gov/pubmed/24371230
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-1589
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares